UNSPSC 51452802: Doramectin

This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KGD7A54H5P. European Medicines Agency schedules Doramectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06369MIG. Doramectin generally arises in the molecular formula C50H74O14.

The term DORAMECTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) DORAMECTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doramectin under HS 29419000 and SITC 54139. As of Q4 2014, DORAMECTIN remains the US FDA Preferred Term for this commodity. Doramectin bears US NLM identifiers UMLS ID C0248572 and NCI Concept Code C81559.

UNSPSC 51452802 Doramectin is a Commodity code that shows minimal recent activity aligned with its nominal scope. The recent opportunities posted under this code do not reflect procurement for doramectin, an antiparasitic veterinary pharmaceutical, but instead track purchases of naloxone, emergency medical supplies, and multi-source generic pharmaceuticals and OTC products for human use across health systems, fire departments, and state pharmacy benefit programs. State and local governments use this code band for pharmaceutical and medical supply acquisitions serving public health, emergency response, and employee benefit programs, though the recent solicitation record reflects a broader miscoding or administrative tagging issue rather than genuine doramectin procurement activity.

The issuing bodies in the recent opportunity set span diverse jurisdictions: Seminole County, Florida (community health); the City of Tampa (fire rescue); the Texas Health and Human Services Commission (pharmacy benefit RFI); and the Minnesota Multistate Cooperative Purchasing Alliance (multi-state pharmacy cooperative). Geographic activity appears concentrated in Florida and Texas, with multi-state reach through MMCAP's Minnesota-administered cooperative serving Oregon and other participating jurisdictions. Representative opportunities include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 drug deactivation systems annually (response due July 26, 2023); the City of Tampa's ITB 26P00145 for medical and first aid supplies totaling an estimated $700,000 with a March 13, 2026 deadline and exclusive SLBE set-aside with a 5 percent bid discount; the Texas HHS Commission's RFI HHS0017013 on direct-to-manufacturer prescription programs (April 3, 2026 response date); and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026. The code warrants closer review to determine whether it is being applied correctly to these procurement activities or whether the opportunities represent miscoding that should direct business development toward more precise pharmaceutical or medical-supply codes.